Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

NCT05155033 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

78

Enrollment

NIH

Sponsor class

Conditions

Metastatic Melanoma
Advanced Locoregional Melanoma
Metastatic Renal Cell Carcinoma
Clear Cell Histology

Interventions

DRUG: Pembrolizumab
DRUG: Aldesleukin

Sponsor

National Cancer Institute (NCI)